Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
- 28 February 2006
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 54 (2) , 149-153
- https://doi.org/10.1016/j.diagmicrobio.2005.08.015
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Population Pharmacokinetic Analysis of Dalbavancin, a Novel LipoglycopeptideThe Journal of Clinical Pharmacology, 2005
- Safety and efficacy of glycopeptide antibioticsJournal of Antimicrobial Chemotherapy, 2005
- In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptideJournal of Antimicrobial Chemotherapy, 2005
- Origin, structure, and activity in vitro and in vivo of dalbavancinJournal of Antimicrobial Chemotherapy, 2005
- Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methodsJournal of Antimicrobial Chemotherapy, 2004
- Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptideInternational Journal of Antimicrobial Agents, 2004
- Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive ActivityJournal of Clinical Microbiology, 2003
- In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 2001
- TeicoplaninDrugs, 1990